Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

From science-backed supplements to insurance-covered nutrition therapy, here's your complete guide to effective weight loss ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

With the TikTok ban approaching, users are seeking alternatives. There are three obvious platforms to migrate to: Red Note, ...

TikTok is still three days away from a likely ban in the United States, but many users are already bidding the app farewell ...

The video above aired on Jan. 15, 2025. QUEENS, N.Y. (PIX11) – With the partial A subway line shutdown starting on Friday, ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Several apps like Lemon8, RedNote, Fanbase and Twitch are getting attention as the date of a potential TikTok ban draws ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

If you’ve recently stopped taking semaglutide—commonly known by brand names like Ozempic or Wegovy—you may be wondering how to transition back to normal while maintaining your health and weight.

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.